187 related articles for article (PubMed ID: 34953602)
1. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
4. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
Wang F; Dong X; Yang F; Xing N
Front Genet; 2022; 13():831146. PubMed ID: 35419031
[No Abstract] [Full Text] [Related]
6. Clinical characterization of radiation-associated muscle-invasive bladder cancer.
Sha ST; Dee EC; Mossanen M; Mahal BA; Zaslowe-Dude C; Royce TJ; Hirsch MS; Sonpavde G; Preston MA; Nguyen PL; Mouw KW; Muralidhar V
Urology; 2021 Aug; 154():208-214. PubMed ID: 33857569
[TBL] [Abstract][Full Text] [Related]
7. Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
Kool R; Marcq G; Breau RH; Black PC; Shayegan B; Kim M; Busca I; Abdi H; Dawidek MT; Uy M; Fervaha G; Cury FL; Alimohamed NS; Izawa JI; Jeldres C; Rendon R; Siemens DR; Kulkarni GS; Kassouf W
Eur Urol Oncol; 2023 Dec; 6(6):597-603. PubMed ID: 37005214
[TBL] [Abstract][Full Text] [Related]
8. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
9. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
10. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K
Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458
[TBL] [Abstract][Full Text] [Related]
12. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
13. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
14. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England.
John JB; Varughese MA; Cooper N; Wong K; Hounsome L; Treece S; McGrath JS; Harden S
Eur Urol Focus; 2021 Mar; 7(2):359-365. PubMed ID: 32088138
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
16. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
17. BCG Administration after Prior Radiation Treatment for Prostate Cancer.
Durant AM; Chang YH; Faraj KS; Tyson MD
Clin Genitourin Cancer; 2022 Dec; 20(6):591-597. PubMed ID: 35798647
[TBL] [Abstract][Full Text] [Related]
18. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
Kim KH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Urol Oncol; 2013 Nov; 31(8):1643-9. PubMed ID: 22591745
[TBL] [Abstract][Full Text] [Related]
19. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
[TBL] [Abstract][Full Text] [Related]
20. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]